Gt Biopharma Inc Quick Ratio (GTBP) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Gt Biopharma Inc   (NASDAQ: GTBP)

Gt Biopharma Inc 's Quick Ratio

GTBP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Gt Biopharma Inc 's Cash & cash equivalent grew by 31.01 % in the Q1 2026 sequentially, faster than Current Liabilities, this led to improvement in Gt Biopharma Inc 's Quick Ratio to 3.69, above Gt Biopharma Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 211 other companies have achieved higher Quick Ratio than Gt Biopharma Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 492 to 765.

Explain Quick Ratio?
How much Cash & cash equivalents GTBP´s has?
What are GTBP´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GTBP Quick Ratio (Mar 31 2026)
Q2		 (Dec 31 2025)
Q1		 (Sep 30 2025)
Q4		 (Jun 30 2025)
Q3		 (Mar 31 2025)
Q2
Y / Y Current Liabilities Change -31.21 % -60.89 % -71.66 % -38.63 % -23.65 %
Y / Y Cash & cash equivalent Change 277.29 % 72.39 % -60.61 % -43.47 % -75.88 %
Quick Ratio MRQ 3.69 2.95 1.91 2.27 0.67
GTBP's Total Ranking # 765 # 492 # 1059 # 826 # 1864
Seq. Current Liabilities Change 4.68 % 74.72 % -42.74 % -34.31 % -40.49 %
Seq. Cash & cash equivalent Change 31.01 % 169.42 % -51.64 % 121.06 % -40.14 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 212
Healthcare Sector # 346
Overall Market # 765


Quick Ratio Statistics
High Average Low
12.06 1.43 0
(Jun 30 2021)   (Jun 30 2014)




Financial Statements
Gt Biopharma Inc 's Current Liabilities $ 2 Millions Visit GTBP's Balance sheet
Gt Biopharma Inc 's Cash & cash equivalent $ 9 Millions Visit GTBP's Balance sheet
Source of GTBP's Sales Visit GTBP's Sales by Geography


Cumulative Gt Biopharma Inc 's Quick Ratio

GTBP's Quick Ratio for the trailling 12 Months

GTBP Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth -53.17 % -50.07 % -33.64 % -18.04 % -20.71 %
Y / Y Cash & cash equivalent TTM Growth 6.86 % -42.46 % -64.33 % -63.37 % -61.94 %
Quick Ratio TTM 2.81 1.79 1.08 1.1 1.23
Total Ranking TTM # 3798 # 2052 # 3188 # 2709 # 3177
Seq. Current Liabilities TTM Growth -11.6 % -27.56 % -20.39 % -8.14 % -5.75 %
Seq. Cash & cash equivalent TTM Growth 38.73 % 20.32 % -21.66 % -18.29 % -25.29 %

Quick ratio ranking by company, industry and sector >> Back to GTBP Financial Strength Comparisons >> Go to Compare GTBP Quick Ratio to its Competitors

On the trailing twelve months basis GTBP Cash & cash equivalent more than doubled by 277.29 % in Q1 2026 year on year, while Current Liabilities rose to $2 millions, this led to increase in in Gt Biopharma Inc 's Quick Ratio to 2.81, above GTBP average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 426 other companies have achieved higher Quick Ratio than Gt Biopharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 2052 to 3798.

Explain Quick Ratio?
How much Cash & cash equivalents GTBP´s has?
What are GTBP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 427
Healthcare Sector # 872
Within the Market # 3798


trailing twelve months Quick Ratio Statistics
High Average Low
6.37 1.19 0
(Mar 31 2022)   (Mar 31 2016)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Revelation Biosciences Inc   9.96 $ 14.113  Millions$ 1.417  Millions
Nektar Therapeutics  9.85 $ 568.604  Millions$ 57.708  Millions
Lipocine Inc   9.78 $ 24.729  Millions$ 2.528  Millions
Boundless Bio Inc   9.69 $ 92.847  Millions$ 9.583  Millions
Promis Neurosciences inc   9.65 $ 63.848  Millions$ 6.615  Millions
Newamsterdam Pharma Company N v   9.54 $ 636.105  Millions$ 66.696  Millions
Silo Pharma Inc  9.53 $ 6.032  Millions$ 0.633  Millions
Kailera Therapeutics Inc   9.47 $ 519.174  Millions$ 54.836  Millions
Erasca Inc   9.14 $ 243.788  Millions$ 26.664  Millions
Anixa Biosciences Inc   9.12 $ 13.686  Millions$ 1.501  Millions
Diamedica Therapeutics Inc   9.11 $ 51.331  Millions$ 5.633  Millions
Acrivon Therapeutics Inc   8.84 $ 97.737  Millions$ 11.054  Millions
Medicinova Inc   8.83 $ 27.329  Millions$ 3.096  Millions
Neuphoria Therapeutics Inc   8.81 $ 13.327  Millions$ 1.513  Millions
Milestone Pharmaceuticals Inc   8.80 $ 184.216  Millions$ 20.944  Millions
Nuvation Bio Inc   8.74 $ 533.729  Millions$ 61.089  Millions
Spyre Therapeutics Inc   8.71 $ 741.467  Millions$ 85.162  Millions
First Tracks Biotherapeutics Inc   8.65 $ 286.455  Millions$ 33.112  Millions
Immix Biopharma Inc   8.59 $ 90.579  Millions$ 10.540  Millions
Kairos Pharma Ltd   8.53 $ 3.675  Millions$ 0.431  Millions
Ataibeckley Inc   8.41 $ 209.858  Millions$ 24.964  Millions
Context Therapeutics Inc   8.34 $ 54.529  Millions$ 6.534  Millions
Capricor Therapeutics inc   8.28 $ 278.610  Millions$ 33.637  Millions
Eledon Pharmaceuticals Inc   8.25 $ 111.089  Millions$ 13.458  Millions
Corbus Pharmaceuticals Holdings Inc   8.16 $ 138.219  Millions$ 16.933  Millions
Biovie Inc   8.13 $ 13.099  Millions$ 1.611  Millions
Aardvark Therapeutics Inc   8.09 $ 91.200  Millions$ 11.268  Millions
Lite Strategy Inc   7.92 $ 7.544  Millions$ 0.952  Millions
Atea Pharmaceuticals Inc   7.82 $ 256.006  Millions$ 32.733  Millions
Bullfrog Ai Holdings Inc   7.79 $ 5.080  Millions$ 0.652  Millions

Date modified: 2026-09-08T17:45:40+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.